Baseline patient characteristics
| Statin naïve patients n=150 | p Value* RA/AS/PsA | Statin users n=47 | p Value* RA/AS/PsA | Statin naïve vs statin users p value | |
|---|---|---|---|---|---|
| Age median (IQR) | 61 (56.0, 67.0) | 0.01 | 65.0 (60.0, 70.0) | 0.004 | 0.01 |
| Sex male/female n (%) | 61/89 (40.7/59.3) | <0.001 | 22/25 (46.8/53.2) | 0.06 | 0.46 |
| Disease duration median (IQR) | 18 (6.0, 26.0) | 0.001 | 25.0 (16.0, 34.5) | 0.04 | 0.001 |
| CV risk factors | |||||
| Smoke n (%) | 28 (18.7) | 0.29 | 10 (21.3) | 0.26 | 0.69 |
| BMI mean±SD | 26.0±4.0 | 0.89 | 26.3±5.2 | 0.41 | 0.78 |
| TC (mmol/L) mean±SD | 6.24±1.16 | 0.75 | 4.97±1.07 | 0.56 | <0.001 |
| HDL-c (mmol/L) mean±SD | 1.68±0.49 | 0.04 | 1.68±0.68 | 0.04 | 0.99 |
| TG (mmol/L) median (IQR) | 1.22 (0.89, 1.69) | 0.69 | 1.24 (0.92, 1.80) | 0.10 | 0.94 |
| LDL-c (mmol/L) mean±SD | 3.92±0.99 | 0.22 | 2.68±0.83 | 0.12 | <0.001 |
| BP systolic (mm Hg) mean±SD | 143.9±20.3 | 0.83 | 150.6±20.0 | 1.00 | 0.05 |
| BP diastolic (mm Hg) mean±SD | 85.0±10.9 | 0.51 | 85.9±10.9 | 0.90 | 0.62 |
| Comorbidities n (%) | |||||
| HT | 97 (64.7) | 0.43 | 41 (87.2) | 0.16 | 0.003 |
| Diabetes | 10 (6.7) | 0.95 | 15 (31.9) | 0.92 | <0.001 |
| CV disease | 48 (32.0) | 0.24 | 27 (57.4) | 0.53 | <0.001 |
| Combined dyslipidaemia | 6 (4.0) | 0.01 | 3 (6.4) | 0.03 | 0.50 |
| Hyperlipidaemia | 85 (56.7) | 0.61 | 8 (17.0) | 0.27 | <0.001 |
| Biomarkers mean±SD | |||||
| ESR (mm/h) | 17.8±16.1 | 0.34 | 18.4±13.9 | 0.42 | 0.82 |
| CRP (mg/L) median (IQR) | 3.0 (1.0, 7.5) | 0.24 | 3.0 (1.0, 7.0) | 0.31 | 0.42 |
| AST (U/L) | 27.7±9.2 | 0.71 | 32.2±20.2 | 0.94 | 0.05 |
| ALT (U/L) | 30.1±18.7 | 0.08 | 37.3±35.0 | 0.94 | 0.07 |
| CK (U/L) | 87.3±48.0 | 0.002 | 98.0±48.4 | 0.67 | 0.22 |
| Medication n (%) | |||||
| Prednisolone | 39 (26.0) | 0.01 | 12 (25.5) | 0.09 | 0.95 |
| NSAIDs | 56 (37.3) | 0.26 | 17 (36.2) | 0.72 | 0.81 |
| sDMARDs | 69 (46.0) | <0.001 | 17 (36.2) | 0.28 | <0.001 |
| bDMARDs | 41 (27.3) | 0.26 | 9 (19.1) | 0.39 | <0.001 |
*p Value describes comparison between patients with RA, AS and PsA.
ALT, alanine aminotransferase; AS, ankylosing spondylitis; AST, aspartate aminotransferase; bDMARDs, biological disease modifying antirheumatic drugs; BMI, body mass index; BP, blood pressure; CK, creatine kinase; CRP, C reactive protein; CV disease, cardiovascular disease (angina pectoris, myocardial infarction, percutaneous coronary intervention, heart surgery, transitory ischaemic attack, stroke, peripheral artery disease); ESR, erythrocyte sedimentation rate; HDL-c, high density lipoprotein cholesterol; HT, hypertension; LDL-c, low density lipoprotein cholesterol; NSAIDs, non-steroid anti-inflammatory drugs; PsA, psoriatic arthritis; RA, rheumatoid arthritis; sDMARDs, synthetic disease modifying antirheumatic drugs; TC, total cholesterol; TG, triglycerides.
Hyperlipidaemia: TC ≥6.0 mmol/L. Combined dyslipidemia: TG ≥2.0 mmol/L and HDL-c ≤1.0 mmol/L.